Monday, November 24, 2008
Launched for the first time by Zydus Group for preventing or delaying Diabetic Neuropathy. It is a Novel Aldosterone Reductase Inhibitor improves neuropathy symptoms in diabetics. Aldonil prevents the deterioration of median Motor Nerve Conduction Velocity (MNCV), improves Vibration Perception Threshold (VPT), reduces the risk of Diabetic Retinopathy and improves Heart Rate Variability (CVR-R) on long term.
To know more about Aldonil, write us at firstname.lastname@example.org
PMT, Zydus Medica